Business Wire

TII

8.3.2021 14:09:09 CET | Business Wire | Press release

Share
Abu Dhabi’s Technology Innovation Institute Appoints International Experts to Board of Advisors at Secure Systems Research Centre

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005482/en/

Secure Systems Research Centre is one of the initial seven dedicated centres at TII and is among the few global centres of its kind to bring together experts to conduct groundbreaking research in the field of secure systems. The distinguished new Board have combined expertise in security and resilience relating to autonomous computing and will guide the efforts of the Centre’s research team in developing end-to-end solutions to protect cyber-physical and autonomous systems.

The Board of Advisors comprises:

Prof. Ernesto Damiani, Professor, Department of Electrical Engineering and Computer Science, Senior Director, Artificial Intelligence & Intelligent Systems Institute, Director of the Center for Cyber Physical Systems (C2PS), Khalifa University in the UAE, whose research interests include secure service-oriented architectures, privacy-preserving big data analytics and cyber-physical systems security.

Dr Hoda Alkhzaimi, Research Assistant Professor at New York University Abu Dhabi (NYUAD) and Director of the University’s Center of Cyber Security, who was associated with research and development posts in cybersecurity and cryptology. Her research interests include unmanned aerial vehicle (UAV) security, cryptology, cryptanalysis, and building security hardware and software components.

Dr Bushra Alblooshi, Head of Research and Innovation at Dubai Electronic Security Center (DESC), who is focused on researching cloud computing, cybersecurity, computer forensics and cryptography.

Prof. Inseok Hwang, Professor at the School of Aeronautics and Astronautics at Purdue University, who specialises in research on intelligent and high assurance autonomy for cyber-physical systems with applications to complex networked systems, such as multi-vehicle systems.

Prof. Dongyan Xu, Samuel D. Conte Professor of Computer Science at Purdue University, specialises in research focused on cyber and cyber-physical security.

Prof. Taesoo Kim is Associate Professor at the School of Computer Science at the Georgia Institute of Technology, and his research interests span systems security architecture and design, threat intelligence, internet infrastructure and operating systems, machine learning, and programming languages.

Prof. Wenke Lee is Professor of Computer Science and John P. Imlay Jr. Chair, College of Computing at the Georgia Institute of Technology, and is one of the most prolific and influential cybersecurity researchers in the world. His research specialty is systems and network security, applied cryptography and machine learning.

Dr Harry Edelman is CEO of architectural consultancy Edelman Group and co-founder of AIDOMUS, a machine learning and IoT-based startup initiative for smart urban services. His work has focused on various aspects of integrated urban developments, including smart urban energy design and mobility.

Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre, said: “The Centre combines fundamental and applied research to set new standards and act as a catalyst to transform problems into solutions. The goal of the research team is to create new technologies for the development of end-to-end security and resilience in cyber-physical and autonomous systems.”

Research in security and resilience in cyber-physical and autonomous systems will ultimately lead to groundbreaking efforts in ensuring the safety and economic prosperity of our communities. The Board of Advisors will guide the expert SSRC researchers in carrying out such cutting-edge research while also creating new opportunities to train aspiring young UAE nationals in these significant fields.

For more information about Secure Systems Research Centre (SSRC), visit tii.ae/securesystems

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit

Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release

Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye